RPR/Fisons tender offer succeeds; RPR sees "irreversible" decline in Intal franchise.
Executive Summary
FISONS TILADE 1994 SALES "ONLY [pound]41 MIL.," or $64 mil., "after eight years on the market," Rhone-Poulenc Rorer declares in its final offer document for its hostile takeover of Fisons. Tilade (nedocromil sodium) "was forecast in 1991 to be a [pound]200 mil. sales product," RPR wrote to Fisons shareholders. RPR contends that Fisons' Intal/Tilade mast-cell stabilizer franchise "is falling substantially behind the growth in the asthma market."